6 Matching Annotations
  1. Feb 2026
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death–Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC12884980/
  3. Nov 2024
  4. bloodcancerdiscov.aacrjournals.org bloodcancerdiscov.aacrjournals.org
    Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    bloodcancerdiscov.aacrjournals.org/content/2/4/354
  5. Aug 2024
  6. aacrjournals.org aacrjournals.org
    Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-23-0062/731565/Transcriptional-Heterogeneity-Overcomes-Super
  7. May 2024
  8. www.nature.com www.nature.com
    The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/s41467-024-48091-w
  9. Feb 2024
  10. aacrjournals.org aacrjournals.org
    Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/bloodcancerdiscov/article/doi/10.1158/2643-3230.BCD-23-0062/731565/Transcriptional-Heterogeneity-Overcomes-Super
  11. Jul 2021
  12. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC8266040/